A placebo-controlled, double-blind, randomised, multicenter study to evaluate the effect of TAK-475 [lapaquistat] 100 mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.

Trial Profile

A placebo-controlled, double-blind, randomised, multicenter study to evaluate the effect of TAK-475 [lapaquistat] 100 mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2017

At a glance

  • Drugs Lapaquistat (Primary)
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda; Takeda Europe Research & Development Centre; Takeda Global Research and Development Center
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Oct 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 28 Mar 2008 Status changed from initiated to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top